Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib. (28th May 2022)

• Record Type: Journal Article
• Authors: Sandhu, Sunny; Chaudhry, Hunza; Zhang, Sharon; Prajapati, Devang
• Other Names: Vigano Mauro Academic Editor.
• Is Part Of: Case reports in hepatology. Volume 2022(2022)
• Publication Date: 2022-05-28
• Subjects: Liver -- Periodicals; Liver -- Diseases -- Periodicals; Liver Diseases; Liver; Liver; Liver -- Diseases; Periodicals; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.36
• DOI: 10.1155/2022/9630996
• Languages: English
• ISSNs: 2090-6587

Abstract

Abstract : Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder seen in older adults which can present both with hepatosplenomegaly as well as mild nonspecific liver enzyme abnormalities. Mild elevations in bilirubin can occasionally be seen due to both intravascular hemolysis as well as extramedullary hematopoiesis. Marked hyperbilirubinemia as a presenting sign of PMF progression, however, has not been reported. We present the case of a patient with a remote diagnosis of PMF, who presented with marked hyperbilirubinemia with a notable response to ruxolitinib.